SERUM OSTEOPROTEGERIN LEVEL IN CHRONIC HAEMODIALYSIS PATIENTS

Abstract

Background: Osteoprotegerin is a powerful inhibitor of osteoclast activity, and it plays an important role in bone metabolism. In hemodialysis (HD) patients, the serum OPG level had been found significantly increased and associated to vascular calcification. Elevated OPG level was noted as a mortality predictor in HD patients. Objective: To assess mean serum osteoprotegerin level in HD patients and to approach the probably relationship between serum osteoprotegerin level and serum PTH, Creatinin, BUN levels in HD patients. Method: Cross – sectional study. Results: Mean serum osteoprotegerin level: 242.49 ± 115.65 pg/ ml. Mean serum BUN level: 58.12 ± 16.83 mg/dL. Mean serum Creatinin level: 6.80 ± 5.23 mg/dL. Mean serum PTH level: 148.52 ± 198.24 pmol/L, median at 66.8 pmol/L [9.2-1140] pmol/L High serum OPG levels were associated with older ages (r=0.464, p<0.001). High serum OPG levels were associated with high BUN (r=0.028, p=0.137) High serum OPG levels were associated with serum Creatinin levels.(r=-0.189, p=0.032). High serum OPG levels were associated with high serum PTH levels (r=0.045, p=0.611). Conclusions: Mean serum osteoprotegerin level in hemodialysis patient: 242.49 ± 115.65 pg/ml. High serum OPG levels were associated with high BUN (r=0.028, p=0.137), with serum Creatinin levels. (r=-0.189, p=0.032), with high serum PTH levels (r=0.045, p=0.611). Key words: End stage renal disease, maintenance haemodialysis, osteoprotegerin, vascular calcification